|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable (net of allowance for credit losses of $10,611 and $6,429 as of June 30, 2024 and December 31, 2023, respectively) | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment | ||||||||||||||||||||
| Less: accumulated depreciation | ||||||||||||||||||||
| Net property, plant and equipment | ||||||||||||||||||||
| Investment in unconsolidated entity | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Net intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| EQT Cash Option (as defined in Note 4) | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Capital contributions payable to the MVP Joint Venture | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term liabilities: | ||||||||||||||||||||
| Revolving credit facility borrowings | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Contract liability | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Regulatory and other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Mezzanine equity: | ||||||||||||||||||||
| Equitrans Midstream Preferred Shares, 30,018 shares issued and outstanding as of June 30, 2024 and December 31, 2023 | ||||||||||||||||||||
| Shareholders' equity: | ||||||||||||||||||||
| Common stock, no par value, 435,013 and 433,505 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively | ||||||||||||||||||||
| Retained deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total common shareholders' equity | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities, mezzanine equity and shareholders' equity | ||||||||||||||||||||
Loading...